KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Takashi Nakano, Satoshi Iwata, Kazunori Oishi, Eriko Iguchi, Yumi Suganuma, Yukio Tada, Shouta Saiki, Kumi Hashimoto, Hitomi Nakajima-Yoshida, Shinya Omoto, Tatsuya Yazaki, Takuhiro Sonoyama

Vaccine 88 128871

PMID42398333
PMCID-
DOI10.1016/j.vaccine.2026.128871
发表日期2026-07-03
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: S-268024 is a recombinant protein vaccine developed as a COVID-19 booster. METHODS: This randomized, observer-blind, phase 3 study enrolled previously vaccinated Japanese adults without a history of SARS-CoV-2 infection. The noninferiority of the immunogenicity of the S-268024 booster vaccination versus NVX-CoV2373 was assessed. RESULTS: The immunogenicity population included 733 (S-268024 group: n = 368; NVX-CoV2373 group: n = 365) of 734 randomized participants. The geometric mean titer (GMT) ratio (95% confidence interval [CI]) was 1.79 (1.52-2.12), and the difference in seroresponse rate (95% CI) of SARS-CoV-2 neutralizing antibody was 7.9% (1.3%-14.4%) on day 29. The lower limit of 95% CI exceeded prespecified margins, indicating noninferior immunogenicity of S-268024 versus NVX-CoV2373; superiority in GMT was also demonstrated. Treatment-related adverse events (AEs) were numerically higher with S-268024 (92.4%) than NVX-CoV2373 (77.5%), with no treatment-related deaths/serious AEs/AEs of special interest. CONCLUSIONS: Interim analyses established noninferiority and superiority of S-268024 to NVX-CoV2373 in immunogenicity, with an acceptable safety profile.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。